Pharmaceutical Resources (PRX) 37.83 0.00

Par Pharmaceutical Cos., Inc.
(PRX) 37.83 0.00

Last Trade:	37.01	Day Range:	36.47 - 37.93
Trade Time:	06:05PM	52wk Range:	24.85 - 42.80
Prev. Close:	37.01	Market Cap:	1.36B
Open:	37.26	Div Yield:	0
Volume:	1138380	PE:
EPS:	0.93

The Latest On PRX

Par Pharmaceutical Acquires Rights to Market and Distribute Generic Dexilant® in the U.S. 4/19/12 3:05pm

Earnings Roundup 2/28/12 11:03am

UPDATE: Par Pharmaceutical Posts Better-Than-Expected Q4 Profit 2/28/12 10:27am

Buckingham Upgrades Par Pharmaceuticals to Buy 1/9/12 11:00am

Can This Pharmaceutical Company Make You Rich? 1/6/12 1:52pm

Are You Guaranteed Profits if These Rumors are True? 12/9/11 3:35pm

Par Pharmaceutical Companies Promotes Thomas J. Haughey to President and Paul V. Campanelli to Chief Operating Officer 11/22/11 9:30am

Intellipharmaceutics Announces Milestone; Analysts Raise Firm's Price Targets Ahead of Another 11/1/11 12:57am

FDA Approves First Generic Olanzapine to Treat Schizophrenia, Bipolar Disorder 10/24/11 3:36pm

Par Pharmaceutical Begins Shipment of Generic Zyprexa Zydis 10/24/11 3:35pm

Par Pharmaceutical Acquires Three Generic Products From Teva Pharmaceuticals 10/18/11 9:01am

Par Pharmaceutical Files Declaratory Judgment to Protect First Amendment Rights to Disseminate Truthful Information Regarding Megace® ES 10/14/11 4:15pm

Par Pharmaceutical Acquires Rights to Market and Distribute Generic Dexilant® in the U.S. 4/19/12

Earnings Roundup 2/28/12

UPDATE: Par Pharmaceutical Posts Better-Than-Expected Q4 Profit 2/28/12

Buckingham Upgrades Par Pharmaceuticals to Buy 1/9/12

Can This Pharmaceutical Company Make You Rich? 1/6/12

Are You Guaranteed Profits if These Rumors are True? 12/9/11

Par Pharmaceutical Companies Promotes Thomas J. Haughey to President and Paul V. Campanelli to Chief Operating Officer 11/22/11

Intellipharmaceutics Announces Milestone; Analysts Raise Firm's Price Targets Ahead of Another 11/1/11

FDA Approves First Generic Olanzapine to Treat Schizophrenia, Bipolar Disorder 10/24/11

Par Pharmaceutical Begins Shipment of Generic Zyprexa Zydis 10/24/11

Par Pharmaceutical Acquires Three Generic Products From Teva Pharmaceuticals 10/18/11

Par Pharmaceutical Files Declaratory Judgment to Protect First Amendment Rights to Disseminate Truthful Information Regarding Megace® ES 10/14/11

Can This Pharmaceutical Company Make You Rich? 1/6/12

Are You Guaranteed Profits if These Rumors are True? 12/9/11

Top 4 Small-Cap Stocks In The Drugs-Generic Industry With The Highest Operating Margin 9/6/11

Financial Breakfast for August 31, 2011 8/31/11

How to Profit from Exploding Government Healthcare Costs 7/28/11

Top 4 Small-Cap Stocks In The Drugs-Generic Industry With The Highest Revenue (PRX, CPD, HITK, AKRX) 5/4/11

Top 4 Small-Cap Stocks In The Drugs-Generic Industry With The Highest Revenue (PRX, CPD, HITK, AKRX) 3/31/11

Top 4 Small-Cap Stocks In The Drugs-Generic Industry With The Highest Cash (SLXP, PRX, CPD, HITK) 3/21/11

Top 4 Stocks In The Drugs-Generic Industry With The Highest Cash (MYL, WPI, PRX, CPD) 11/18/10

Top 4 Stocks In The Drugs-Generic Industry With The Highest ROE (HITK, PRX, WPI, MYL) 7/12/10

Top 4 Stocks In The Drugs-Generic Industry With The Highest EPS Estimates (WPI, HITK, PRX, MYL) 7/12/10

Puts Bought on Par Pharma (PRX) 6/8/10

Buckingham Upgrades Par Pharmaceuticals to Buy 1/9/12

UPDATE: Bank of America Merrill Lynch Raises PO on Par Pharmaceuticals Companies to $39 8/31/11

Financial Breakfast for August 31, 2011 8/31/11

Bank of America Raises PO On Par Pharmaceutical Companies To $39 8/31/11

Goldman Sachs Tweaks PRX Estimates 2/25/11

Goldman Sachs Rates Par Pharmaceutical Neutral (PRX) 1/13/11

PRX, ALKS, Initiated At Buy 9/30/10

Cowen stays Neutral On Santarus (SNTS), Cites Litigation Concerns , PRX, MRK, AZN, NVS 12/2/09

Par Pharmaceutical: Dec 3 Analyst Day Preview 11/30/09

Trade PRX
NOW!

Partner Headlines

Par Pharmaceuticals Companies, Inc. - Value 5/15/12

Par Pharmaceutical Companies Inc. Reports Operating Results (10-Q) 5/8/12

Par Pharma 5/8/12

New Analyst Coverage 4/20/12

Par Pharma Acquires Handa's ANDA - Analyst Blog 4/20/12

Par Pharma Launches Generic Provigil - Analyst Blog 4/11/12

WCG, CL, SJM, PRX Hit 52-Week Highs 3/30/12

PRX Outperforms; Reaffirms Guidance - Analyst Blog 3/5/12

Par Pharmaceutical Companies Inc. Reports Operating Results (10-K) 2/28/12

Par Pharma Absorbs Edict Pharma - Analyst Blog 2/22/12

Get These 5 Stocks While They're Hot - Investment Ideas 1/27/12

Press Releases

Par Pharmaceutical Companies Reports First Quarter 2012 Results 5/8/12 Newswire

Par Pharmaceutical Acquires Rights to Market and Distribute Generic Dexilant® in the U.S. 4/19/12 Newswire

Par Pharmaceutical Begins Shipment of Generic Provigil® 4/6/12 Newswire

Par Pharmaceutical Companies Reports Fourth Quarter and Full-Year Results for 2011 2/28/12 Newswire

"Drucker on the Dial" Recognized by the Public Radio Exchange 2/10/12 PRWeb

Robbins Umeda LLP Announces an Investigation of Par Pharmaceutical Companies, Inc. 2/6/12 Business Wire

Par Pharmaceutical Companies to Report Fourth Quarter and Full Year 2011 Results on February 28, 2012 1/31/12 Newswire

Par Pharmaceutical to Host Analyst Day on January 6, 2012 12/5/11 Newswire

Get the latest PRX stock news on the web. Get the latest stock quotes and much more - Benzinga is the source for Par Pharmaceutical Cos., Inc. stock price.

Par Pharmaceutical Cos., Inc. by YCharts

Pharmaceutical Resources (PRX) 37.83 0.00

Quotes

Analysis

Twitter

Ownership

Earnings

The Latest On PRX

From Benzinga's Newsdesk

Benzinga's News Delivered Free

Latest from Premium

Brain Trust

Popular Channels

Tools & Features

About Benzinga

Social